Biosimilars in inflammatory bowel disease: A review of post-marketing experience

CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease

(2016) Kornelius Schulze et al.   BIOLOGICALS

Development of biosimilars

(2016) Ahmad AL-Sabbagh et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients

(2016) Jørgen Jahnsen   Therapeutic Advances in Gastroenterology

Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center

(2015) Klaudia Farkas et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

(2015) Shomron Ben-Horin et al.   GUT

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

(2015) Krisztina B. Gecse et al.   Journal of Crohns & Colitis

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations

(2015) J. Sieczkowska et al.   Journal of Crohns & Colitis

Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study

(2015) Yoon Suk Jung et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea

(2015) Sang Hyoung Park et al.   Expert Review of Gastroenterology & Hepatology

Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study

(2015) Jørgen Jahnsen et al.   Expert Review of Gastroenterology & Hepatology

The challenge of indication extrapolation for infliximab biosimilars

(2014) Brian G. Feagan et al.   BIOLOGICALS

Biosimilars: the science of extrapolation

(2014) M. Weise et al.   BLOOD

Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease

(2014) Vito Annese et al.   DIGESTIVE AND LIVER DISEASE

Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

(2014) Yun-Seong Kang et al.   DIGESTIVE DISEASES AND SCIENCES

Biosimilars: In support of extrapolation of indications

(2014) Hans C. Ebbers   Journal of Crohns & Colitis

Inflammatory pathways of importance for management of inflammatory bowel disease

(2014) Jannie Pedersen   WORLD JOURNAL OF GASTROENTEROLOGY

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

(2013) Dae Hyun Yoo et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

(2013) Won Park et al.   ANNALS OF THE RHEUMATIC DISEASES

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

The burden of inflammatory bowel disease in Europe

(2013) Johan Burisch et al.   Journal of Crohns & Colitis

Developing Oncology Biosimilars: An Essential Approach for the Future

(2013) Jame Abraham   SEMINARS IN ONCOLOGY

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

(2010) Matthieu Allez et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)

(2008) Inger Camilla Solberg et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY